Ervin Epstein
ORLANDO—A rare inherited form of skin cancer — basal cell nevus syndrome — has been controlled by an inhibitor of the “hedgehog” molecular pathway in a study reported to the American Association for Cancer Research annual meeting held in Orlando. Ervin Epstein, Senior Scientist at the Children’s Hospital of the Oakland Research Institute in California, presented the first drug study in man to harness the anti-hedgehog pathway for treating cancer. He talks with ecancer radio about the importance of his group’s findings.
